Switzerland’s drug regulator has approved the world’s first malaria treatment for newborn babies, clearing the way for the medicine to become available in parts of Africa where the life-threatening disease is endemic.
In a late-stage clinical trial, pharmaceutical giant Novartis showed the drug was safe and effective for babies weighing less than five kilograms, which they typically reach by two months of age.
